ライフサイエンスコーパス: radiation therapy

1 tment modalities (systemic therapy, surgery, radiation therapy).

2 low-up of 5 years and no history of previous radiation therapy).

3 drogen deprivation therapy and external-beam radiation therapy).

4 imitation to improve tumor control following radiation therapy.

5 l and in women who received chemotherapy and radiation therapy.

6 None received radiation therapy.

7 for the response of HPV16-positive tumors to radiation therapy.

8 l surgery and 85/333 (25.5%) underwent prior radiation therapy.

9 istine, dactinomycin and doxorubicin) but no radiation therapy.

10 ly enhance the cancer cell killing effect of radiation therapy.

11 eir enhanced proliferation and resistance to radiation therapy.

12 icate that neutrophils promote resistance to radiation therapy.

13 ing with cyclophosphamide and etoposide) and radiation therapy.

14 nt therapy when treating pelvic cancers with radiation therapy.

15 L were frequently treated with external beam radiation therapy.

16 e use of antioxidants during chemotherapy or radiation therapy.

17 reased response of HPV16-positive cancers to radiation therapy.

18 tion enables potentially definitive doses of radiation therapy.

19 ets in the vast non-coding genome to enhance radiation therapy.

20 alone is now recommended for low-emetic-risk radiation therapy.

21 III FHWT were treated with Regimen DD4A and radiation therapy.

22 ues or for participating in tumor control by radiation therapy.

23 adopted regimens such as chemotherapy and/or radiation therapy.

24 mical relapse after surgery or external-beam radiation therapy.

25 y allow for higher and more regular doses of radiation therapy.

26 mproved surgical strategies and systemic and radiation therapy.

27 e had expanders removed for infection before radiation therapy.

28 recurrence of prostate cancer after primary radiation therapy.

29 m delivery planning, and intensity-modulated radiation therapy.

30 cristine, dactinomycin, and doxorubicin) and radiation therapy.

31 tissue damage and improving tumor control in radiation therapy.

32 y) or daily placebo tablets during and after radiation therapy.

33 ion associated with short-term relapse after radiation therapy.

34 quent surgery with adjuvant chemotherapy and radiation therapy.

35 One patient had also undergone prior radiation therapy.

36 had good EFS/overall survival with DD4A and radiation therapy.

37 inadequate follow-up (<1 year) and previous radiation therapy.

38 s the basis for recommendations for adjuvant radiation therapy.

39 sure the safe delivery of selective internal radiation therapy.

40 iomics features changed significantly during radiation therapy.

41 186) to the nodes alone or stereotactic body radiation therapy.

42 as been shown to regulate tumor responses to radiation therapy.

43 from patients treated with stereotactic body radiation therapy.

44 prove efficacy in cancer patients undergoing radiation therapy.

45 participants with cancer before and after a radiation therapy.

46 al blood stem cell rescue and involved-field radiation therapy.

47 ning immunity and enhances responsiveness to radiation therapy.

48 ually, and both often require treatment with radiation therapy.

49 s such as secondary malignancy compared with radiation therapy.

50 in, vincristine, and prednisone (R-CHOP) and radiation therapy.

51 e tumor growth and sensitize glioma cells to radiation therapy.

52 re tumor size greater than 3 cm and previous radiation therapy.

53 roved survival with temozolomide compared to radiation-therapy.

54 dysplastic, and are refractory to chemo and radiation therapies.

55 ations secondary to cardiotoxic systemic and radiation therapies.

56 nd three-dimensional conformal external beam radiation therapy (3D-CRT) have not been compared prospe

57 to Lung-RADS category 4B or 4X was 80% after radiation therapy (49 945 of 62 559; 95% CI: 80%, 80%),

58 (69.2%), were retired (62.4%), and underwent radiation therapy (56.7% v 46.2% who underwent surgery),

59 cy was not influenced by prior external-beam radiation therapy (79.1% vs. 82.1%, P = 0.55), androgen

60 nderwent 2 PET/CT scans (1-3 d apart) before radiation therapy: a 3-min static (18) F-FDG and a dynam

61 iopsy, chemotherapy, or internal or external radiation therapy, according to the clinical schedule; p

62 everal strategies to improve the efficacy of radiation therapy against hepatocellular carcinoma (HCC)

63 ril 15, 2001, were identified, randomized to radiation therapy alone or radiation therapy followed by

64 lar tachycardia (VT) using stereotactic body radiation therapy, although prospective data are lacking

65 current antioxidant use with chemotherapy or radiation therapy among 1940 women was associated with i

66 nformation and guidance on treatment such as radiation therapy and chemotherapy after surgery.

67 Conversely, radiation therapy and chemotherapy induce DNA damage to

68 She received adjuvant radiation therapy and initiated letrozole, with excellen

69 systemic neoplasms shown to be curable with radiation therapy and multiagent chemotherapy.

70 age-guided interventional procedures such as radiation therapy and needle biopsy, and might help simp

71 levels lower than 0.2 ng/mL (n = 13), after radiation therapy and not meeting the Phoenix criteria (

72 l of 0.2 to 4.0 ng per milliliter to undergo radiation therapy and receive either antiandrogen therap

73 ween cumulative exposure to chemotherapy and radiation therapy and selected comorbidities were examin

74 aging as prognostic, overall, and in primary radiation therapy and surgery subgroups, but ultimately

75 lts suggest radiomics features change due to radiation therapy and their values at the end of treatme

76 han prior results combining gemcitabine with radiation therapy and warrants additional investigation.

77 inary; it includes locoregional (surgery and radiation therapy) and systemic therapy approaches.

78 nd thus, do not respond to chemotherapies or radiation therapies, and they are not operable.

79 years), 22 patients (92%) had received prior radiation therapy, and 15 patients (63%) had received tw

80 n or equal to 50%, prior chemotherapy, prior radiation therapy, and baseline hemoglobin level were as

81 mended adjuvant chemotherapy, postmastectomy radiation therapy, and endocrine therapy.

82 ommended adjuvant chemotherapy, postsurgical radiation therapy, and endocrine therapy.

83 chronic complications, intravenous drug use, radiation therapy, and solid organ transplantation.

84 CH was associated with increased age, prior radiation therapy, and tobacco use.

85 with cancer immunotherapy, chemotherapy, and radiation therapy, and we review their potential as targ

86 ntracranial ependymoma treated with surgery, radiation therapy, and-selectively-with chemotherapy.

87 factor for minor complications was previous radiation therapy (AOR, 2.2 [95% CI: 1.0, 4.7]; P = .04)

88 .4 [95% CI: 1.2, 4.5]; P = .03) and previous radiation therapy (AOR, 3.8 [95% CI: 2.0, 7.4]; P = .02)

89 ors of childhood cancer treated with cranial radiation therapy are at risk for subsequent CNS tumors.

90 hil count, but the effects of neutrophils on radiation therapy are controversial.

91 lar toxic effects of cancer therapeutics and radiation therapy are the epitome of such concerns, and

92 rial radioembolization and stereotactic body radiation therapy) are different than those seen after t

93 ta for 10,350 patients were analyzed from 15 radiation therapy-based trials enrolled from 1987 to 201

94 als of prostate cancer therapies for primary radiation therapy-based trials.

95 apies, such as anthracycline, trastuzumab or radiation therapy, but even more so with an ever-increas

96 diosensitivity and increased the efficacy of radiation therapy by curtailing PDAC cell motility and i

97 No difference in the use of surgery or radiation therapy by location was found.

98 onated (H-RT) or conventionally fractionated radiation therapy (C-RT) in a national cohort study.

99 Extensive surgery and chemo/radiation therapy (C/RT) to manage head and neck cancer

100 of treatment.Keywords: MR-Imaging, Prostate, Radiation Therapy(C) RSNA, 2020See the commentary by Dav

101 Radiation therapy can result in pathological fibrosis of

102 environmental agents or treatments, such as radiation therapy, can diminish healthspan and accelerat

103 Imaging Cherenkov emission during radiation therapy cancer treatments can provide a real-t

104 involves a regiment of radical prostectomy, radiation therapy, chemotherapy and hormonal therapy.

105 LFIRINOX-based therapy and stereotactic body radiation therapy correlated with increased probability

106 CR) to neoadjuvant combined chemotherapy and radiation therapy (CRT) in patients with rectal cancer.

107 urgery and immediate postoperative conformal radiation therapy (CRT).

108 or CPS+EG scores >/=3, use of postmastectomy radiation therapy decreases the likelihood of LRR after

109 -fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-infer

110 Thus, selective internal radiation therapy demands an expert multidisciplinary te

111 Stereotactic body radiation therapy demonstrated the best outcomes compare

112 adult survivors of childhood cancer who had radiation therapy do not practice strategies that promot

113 elevant for research in targeting agents and radiation therapy dose escalation.

114 Radiation therapy dose was categorized into 4 groups: gr

115 ning age at primary cancer, sex, and cranial radiation therapy dose yielded an area under the curve o

116 rials comparing dose-escalated external beam radiation therapy (EBRT) with brachytherapy in men with

117 ed with radical prostatectomy, external beam radiation therapy (EBRT), and active surveillance.

118 ssified into three groups: (1) external beam radiation therapy (EBRT); (2) brachytherapy (BT); (3) bo

119 aring prostatectomy (n = 675), external beam radiation therapy (EBRT; n = 261), or low-dose-rate brac

120 ing paradigm for enhancing colorectal cancer radiation therapy efficacy.

121 agnosis, history of abdominal surgery, prior radiation therapy, evidence of peritoneal carcinomatosis

122 ficant associations between chemotherapy and radiation therapy exposures and late effects of cardiomy

123 ed, randomized to radiation therapy alone or radiation therapy followed by 6 months of androgen depri

124 with a positive iPET received involved field radiation therapy followed by ibritumomab tiuxetan radio

125 During the early decades of radiation therapy for breast cancer, local control of di

126 h the advancement of treatment modalities in radiation therapy for cancer patients, outcomes have imp

127 the possibility of developing a new type of radiation therapy for cancer.

128 after preoperative combined chemotherapy and radiation therapy for cervical carcinoma and evaluate th

129 ded to assess benefits and risks of adjuvant radiation therapy for each patient with N2 disease.

130 ASCO endorsed the ASTRO guideline on radiation therapy for glioblastoma and added qualifying

131 Methods The ASTRO guideline on radiation therapy for glioblastoma was reviewed for deve

132 TRO) produced an evidence-based guideline on radiation therapy for glioblastoma.

133 Radiation therapy for head and neck cancers results in p

134 All patients who underwent radiation therapy for localized prostate cancer between

135 Tumor regression after radiation therapy for melanomas was associated with decr

136 precision, efficiency and overall quality of radiation therapy for patients with cancer.

137 rm and potential for benefit associated with radiation therapy for patients with extrahepatic cholang

138 reviews and a search for studies related to radiation therapy found no additional randomized control

139 nderwent (18)F-FDG PET/CT before systemic or radiation therapy from 2004 to 2017.

140 ransarterial chemo- or radioembolization, or radiation therapy from January 2013 through December 201

141 ransarterial chemo- or radioembolization, or radiation therapy, from January 2013 through December 20

142 oderate hypofractionated intensity-modulated radiation therapy (H-IMRT) versus conventionally fractio

143 Additionally, radiation therapy has been proposed as a means to recrui

144 Radiation therapy has been shown to enhance the efficacy

145 The paradigm for post-operative cavity radiation therapy has shifted to more targeted, less mor

146 ology developments in diagnostic imaging and radiation therapy have elucidated parts of this enigma.

147 New developments in radiation therapy have improved recurrence-free survival

148 ciation with menopausal status, prior breast radiation therapy, hormonal treatment, breast density on

149 on may represent a valid target for boosting radiation therapy immunogenicity in patients with breast

150 robotic surgery, dynamic intensity-modulated radiation therapy, immunotherapy, and de-escalation tria

151 -site cCR to IC received intensity-modulated radiation therapy (IMRT) 54 Gy with weekly cetuximab; th

152 tely predict the dose of intensity-modulated radiation therapy (IMRT) for prostate cancer patients, w

153 Purpose Although intensity-modulated radiation therapy (IMRT) is increasingly used to treat l

154 compared the toxicity of intensity-modulated radiation therapy (IMRT) to the prostate and the pelvic

155 f brachytherapy or 38.5 Gy of external bream radiation therapy in 10 fractions, over 5 treatment days

156 rgone initial prostatectomy, with additional radiation therapy in 19.3% of patients and androgen-depr

157 in 297 (17%) and mastectomy + postmastectomy radiation therapy in 744 (44%).

158 This radioprotection enables ablative radiation therapy in a mouse model of pancreatic cancer

159 reatment protocol for (225)Ac-PSMA-617 alpha-radiation therapy in advanced-stage, metastatic castrati

160 Because cetuximab enhances the effect of radiation therapy in human papilloma virus-associated or

161 Because cetuximab enhances the effect of radiation therapy in human papilloma virus-associated or

162 support the use of H-RT as the standard for radiation therapy in men with nonmetastatic PCa.

163 TRO) produced an evidence-based guideline on radiation therapy in oropharyngeal squamous cell carcino

164 h checkpoint inhibitors, chemotherapy and/or radiation therapy in preclinical studies.

165 ending resections or applying intraoperative radiation therapy in the case of positive CRM.

166 sitivity of mouse mammary carcinoma cells to radiation therapy in vitro and in vivo (in immunocompete

167 ighlight caspase-independent cytotoxicity in radiation therapy-induced antitumor immunity, proposing

168 nations with chemotherapy, targeted therapy, radiation therapy, intratumoural therapies, other immuno

169 Single-fraction or hypofractionated radiation therapy is a common approach to treating the p

170 Purpose Radiation therapy is a critical component in the care of

171 Cranial radiation therapy is associated with white matter-specif

172 Radiation therapy is beneficial but not curative, with t

173 Radiation therapy is capable of directing adaptive immun

174 mline TP53 mutations, mastectomy is advised; radiation therapy is contraindicated except in those wit

175 Adjuvant radiation therapy is not recommended for patients with r

176 atients with stage IIIA N2 disease, adjuvant radiation therapy is not recommended for routine use.

177 Salvage radiation therapy is often necessary in men who have und

178 Radiation therapy is the most effective cytotoxic therap

179 litating toxicity associated with chemo- and radiation therapies, is a significant unmet clinical nee

180 In cancer radiation therapy, large tumor motion due to respiration

181 cteristics (no chemotherapy, splenectomy, or radiation therapy; male; attained age 28 years).

182 iated enhancement of MMEJ in cells surviving radiation therapy may contribute to their radioresistanc

183 vant release or active suppression following radiation therapy may limit its efficacy in poorly radio

184 ic biomarker of biochemical recurrence after radiation therapy, metastasis and cancer-specific mortal

185 Conventional radiation therapy of brain tumors often produces cogniti

186 agents to act in conjunction with chemo- or radiation therapy of cancer cells.

187 nificant challenges to proper positioning in radiation therapy of head and neck cancers.

188 te proliferation of and confer resistance to radiation therapy of PDAC.

189 Radiation therapy often accelerates atherosclerosis.

190 rway to understanding the powerful impact of radiation therapy on both breast cancer and critical org

191 vailable demonstrate a significant impact of radiation therapy on survival as well as disease control

192 ect surgery interaction with chemotherapy or radiation therapy on survival by using the National Canc

193 ssociated with worse overall survival in the Radiation Therapy Oncology Group (RTOG) 0617 study.

194 y substudy were worst grade 2 or more severe Radiation Therapy Oncology Group (RTOG) gastrointestinal

195 clinical target volumes (CTVs) based on the Radiation Therapy Oncology Group (RTOG) guidelines cover

196 Radiation Therapy Oncology Group 9413, a 2 x 2 factorial

197 ere obtained: Ottawa 0101 and NRG Oncology's Radiation Therapy Oncology Group 9413.

198 atinum-based chemoradiotherapy (NRG Oncology Radiation Therapy Oncology Group [RTOG] 0129 and 0522).

199 to compare the incidence of acute mucositis (Radiation Therapy Oncology Group and WHO scales) and 36-

200 e delivery to nodes outside the conventional Radiation Therapy Oncology Group volumes, where magnetic

201 gastrointestinal toxicity as defined by the Radiation Therapy Oncology Group was compared between th

202 onsisted of patients with a history of brain radiation therapy or craniotomy who underwent 1.5-T and

203 y been treated by fractionated external beam radiation therapy or invasive brachytherapy.

204 tients were previously randomized to receive radiation therapy or radiation and 6 months of androgen

205 Selective internal radiation therapy (or radioembolization) by intra-arteri

206 (OR, 1.96), intravenous drug use (OR, 3.12), radiation therapy (OR, 5.28), and solid organ transplant

207 use of appropriate local treatments such as radiation therapy, orthopaedic surgery and specialist pa

208 y oncology specialists in medicine, surgery, radiation therapy, palliative care, nursing, and patholo

209 eation in non-small cell lung cancer (NSCLC) radiation therapy planning by using pathology volumes as

210 ques and the adoption of intensity-modulated radiation therapy planning have been transformative in d

211 The use of postmastectomy radiation therapy (PMRT) has been recommended for patien

212 e Conventionally fractionated postmastectomy radiation therapy (PMRT) takes approximately 5 to 6 week

213 The volume treated with postoperative radiation therapy (PORT) is a mediator of toxicity, and

214 However, cranial radiation therapy produces long-term impairment in memor

215 In this study, we report that radiation therapy promotes the activation of intratumora

216 Despite surgery and chemo/radiation therapy, recurrence often takes place and lead

217 Radiation therapy remains the mainstay for treatment of

218 le of radiation-induced bystander effects in radiation therapy remains unclear.

219 gion is rare, and the utility of surgery and radiation therapy remains unresolved.

220 in using magnetic resonance imaging only in radiation therapy require methods for predicting the com

221 Current strategies utilizing whole brain radiation therapy result in deleterious off-target effec

222 e that genotoxic stress from chemotherapy or radiation therapy, ribosome biogenesis stress, and possi

223 espite best treatment by surgical resection, radiation therapy (RT) and chemotherapy with temozolomid

224 nuates antitumor immune responses induced by radiation therapy (RT) by inhibiting the release of cyto

225 Radiation therapy (RT) can enhance immune recognition of

226 Radiation therapy (RT) cannot yet substitute for an oper

227 Radiation therapy (RT) continues to be one of the mainst

228 To determine the optimal adjuvant radiation therapy (RT) dose following resection of local

229 ) remains a common, debilitating toxicity of radiation therapy (RT) for head and neck cancer.

230 Radiation therapy (RT) including external beam radiother

231 Radiation therapy (RT) is a cornerstone of treatment in

232 Radiation therapy (RT) is commonly used to treat solid t

233 The abscopal effect following ionizing radiation therapy (RT) is considered to be a rare event.

234 ombination of photodynamic therapy (PDT) and radiation therapy (RT) more significantly inhibits tumor

235 osis (RIPF) is a debilitating side effect of radiation therapy (RT) of several cancers including lung

236 LNPs was robustly enhanced in the context of radiation therapy (RT) owing to the RT-induced up-regula

237 Radiation therapy (RT) provides survival benefit of 6 mo

238 In vivo LOFU followed by ablative radiation therapy (RT) results in primary tumor cure, up

239 Until recently, radiation therapy (RT) was believed to mediate antineopl

240 n patients with stage I disease treated with radiation therapy (RT), doses >/=30.6 Gy were associated

241 or combined cancer therapy, photothermal and radiation therapy (RT), multimodal imaging, theranostics

242 o-thirds of cancer patients are treated with radiation therapy (RT), often with the intent to achieve

243 Chk1/2 inhibitor AZD7762 is used to abrogate radiation therapy (RT)-induced G2/M cell cycle arrest in

244 dynamic biomarkers for personalized adaptive radiation therapy (RT).

245 argin width and LRR with or without adjuvant radiation therapy (RT).

246 l-like breast cancer (BC) despite the use of radiation therapy (RT); therefore, approaches that resul

247 Stereotactic body radiation therapy (SBRT) is a novel treatment for refrac

248 the cost-effectiveness of stereotactic body radiation therapy (SBRT) versus radiofrequency ablation

249 Stereotactic body radiation therapy (SBRT), in which a high daily radiatio

250 se ablative radiation with stereotactic body radiation therapy (SBRT).

251 Radiation therapy should not be withheld in ATM carriers

252 A)-617 ((177)Lu-PSMA) and selective internal radiation therapy (SIRT) for the treatment of liver meta

253 Selective internal radiation therapy (SIRT) has been tested as salvage ther

254 -response relationship of selective internal radiation therapy (SIRT) in patients with metastatic col

255 fit has been observed for selective internal radiation therapy (SIRT) over sorafenib in patients with

256 frican-American patients, patients receiving radiation therapy, stage IV patients, and melanoma patie

257 nt strategies were tested (stereotactic body radiation therapy, surgery, and no therapy).

258 ific membrane antigen (PSMA)-targeting alpha-radiation therapy (TAT) is an emerging treatment modalit

259 t survivors of childhood cancer who received radiation therapy than among the general population, the

260 avirus (HPV) are far more readily cured with radiation therapy than HPV-negative SCCs.

261 , decision making with regard to surgery and radiation therapy, the importance of rehabilitative care

262 After initiation of radiation therapy, the proportion of PD-L1(+) CTCs incre

263 vasive, acoustic immune priming and ablative radiation therapy to generate an in situ tumor vaccine,

264 mising candidate for use in combination with radiation therapy to manage PDAC.

265 r longer than 8 weeks, and (3) no history of radiation therapy to the jaws or metastatic disease to t

266 d CRT including cisplatin, fluorouracil, and radiation therapy to the primary tumor and regional lymp

267 and HIV infection received CRT: 45 to 54 Gy radiation therapy to the primary tumor and regional lymp

268 trategy involving fractionated partial brain radiation therapy to the surgical cavity.

269 The radiation therapy-treated brain tumor group demonstrated

270 in tumor group were higher than those in the radiation therapy-treated brain tumor group for doses gr

271 of the chest, PET attenuation correction CT, radiation therapy treatment planning CT, CAC screening C

272 era sensing of Cherenkov emission during the radiation therapy treatment.

273 III NSCLC treated on one of four prospective radiation therapy trials at two centers from 2004 to 201

274 emonstrated no survival difference comparing radiation-therapy versus temozolomide monotherapies.

275 alizing the extent of surgical resection and radiation therapy volumes.

276 Antioxidant use during chemotherapy or radiation therapy was associated with worsened breast ca

277 (HR, 0.5; 95% CI, 0.3-0.9; P = .04), whereas radiation therapy was not.

278 Local tumor control with surgery and/or radiation therapy was permitted after 6 weeks of treatme

279 Radiation therapy was provided for postchemotherapy stag

280 dence of late adverse events associated with radiation therapy was similar in the two groups.

281 Chemotherapy with or without external beam radiation therapy was the most frequently used treatment

282 AZD1775 in combination with gemcitabine and radiation therapy was well tolerated at a dose that prod

283 n cancer-directed surgery, chemotherapy, and radiation therapy were combined (hazard ratio, 0.52).

284 chedule; patients with prior chemotherapy or radiation therapy were excluded.

285 Iris melanoma patients treated with radiation therapy were imaged again after I-125 plaque b

286 Cancer-directed surgery, chemotherapy, and radiation therapy were independently associated with imp

287 eatment-response scans after chemotherapy or radiation therapy were obtained for 17 patients.

288 radiation dose and the curative potential of radiation therapy when treating larger target volumes.

289 evealed that the addition of chemotherapy to radiation therapy, whether sequentially or concurrently,

290 d to monitor dynamic changes of PD-L1 during radiation therapy which is potentially prognostic of res

291 treated first with combined chemotherapy and radiation therapy, who underwent MR imaging before final

292 Whether antiandrogen therapy with radiation therapy will further improve cancer control an

293 des glucocorticoid therapy, pain management, radiation therapy with or without surgery, and specializ

294 ctively recruited after prostatectomy and/or radiation therapy with rising prostate-specific antigen

295 C) patients administered intensity-modulated radiation therapy with simultaneous integrated boost (SI

296 C) patients are prescribed with chemo and/or radiation therapies, with 5-year relative survival rates

297 the larynx by using endoscopic resection or radiation therapy, with either leading to similar outcom

298 nagement of patients who were restaged after radiation therapy without meeting the Phoenix criteria f

299 ac imaging with a standard stereotactic body radiation therapy workflow followed by delivery of a sin

300 ds, followed by a high-level overview of the radiation therapy workflow with discussion of the implic